X, Z., L, S., Y, W., J, L., J, Z., R, C., . . . H, Y. (2021). Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI. Dove Medical Press.
Style de citation Chicago (17e éd.)X, Zhao, et al. Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI. Dove Medical Press, 2021.
Style de citation MLA (8e éd.)X, Zhao, et al. Proprotein Convertase Subtilisin/Kexin Type 9 and Systemic Inflammatory Biomarker Pentraxin 3 for Risk Stratification Among STEMI Patients Undergoing Primary PCI. Dove Medical Press, 2021.
Attention : ces citations peuvent ne pas être correctes à 100%.